MarketPeel
Insider Trading Intelligence
Pricing
…
CN

Claude Nicaise

GANX
DIRECTOR · GAIN THERAPEUTICS, INC. · CIK 0001644162
FILING MIX · LIFETIME88%/12%
BUYS
28
SELLS
4
TOTAL VALUE
$781.5K
COMPANIES
4
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
101,791
AVG SELL PX
$42.30
TRADE KIND
SHOWING 32 / 32
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 1 pending
Forward-return performance of every backtestable P/S trade by Claude Nicaise, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%-19.85%+1.48%-21.32%-21.32%—
14d1+100.00%-26.95%+2.04%-29.00%-29.00%—
30d1+100.00%-48.85%-4.17%-44.68%-44.68%—
60d1+100.00%-63.55%+4.63%-68.18%-68.18%—
90d1+100.00%-60.84%+8.23%-69.08%-69.08%—
180d1+100.00%-82.36%+16.45%-98.81%-98.81%—
1y1+100.00%-82.92%+19.54%-102.46%-102.46%—
2y1(1 pending)——————
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
GANX · 15,000 shares · as of Jun 24, 2025
03,7507,50011,25015,000202320242025SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 28 buys / 4 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
16,875——48,407Jun 4, 2026Jun 5, 2026 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASE
10,500$13.71$144.0K38,312Jan 29, 2026Jan 29, 2026 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
SALE
6,780$21.23$143.9K31,532Jan 29, 2026Jan 29, 2026 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
SALE
10,500——0Jan 29, 2026Jan 29, 2026 ↗View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,000——15,000Jun 24, 2025Jun 25, 2025 ↗View →
SAVA
FILANA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
26,500——26,500May 23, 2025May 27, 2025 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
SALE
2,491$99.64$248.2K27,812Mar 12, 2025Mar 13, 2025 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
SALE
9,746——0Mar 12, 2025Mar 13, 2025 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASE
9,746$25.18$245.4K30,303Mar 12, 2025Mar 13, 2025 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,792——20,557Mar 10, 2025Mar 11, 2025 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,383——20,557Mar 10, 2025Mar 11, 2025 ↗View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,000——15,000Jun 24, 2024Jun 26, 2024 ↗View →
SAVA
FILANA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,000——10,000May 9, 2024May 13, 2024 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
3,679——3,679Mar 1, 2024Mar 5, 2024 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,846——18,174Mar 1, 2024Mar 5, 2024 ↗View →
SAVA
FILANA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,000——20,000Dec 6, 2023Dec 8, 2023 ↗View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,500——10,500Jun 23, 2023Jun 26, 2023 ↗View →
CMMB
CHEMOMAB THERAPEUTICS LTD.
PURCHASEGRANT
Stock grant
6,857——6,857Mar 16, 2023Mar 23, 2023 ↗View →
CMMB
CHEMOMAB THERAPEUTICS LTD.
PURCHASEGRANT
Stock grant
6,820——6,820Mar 16, 2023Mar 23, 2023 ↗View →
CMMB
CHEMOMAB THERAPEUTICS LTD.
PURCHASEGRANT
Stock grant
11,884——11,884Mar 16, 2023Mar 23, 2023 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
3,257——3,257Mar 6, 2023Mar 8, 2023 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,523——16,328Mar 6, 2023Mar 8, 2023 ↗View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,500——10,500Sep 20, 2022Sep 22, 2022 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,953——14,805Mar 7, 2022Mar 8, 2022 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,077——5,077Mar 7, 2022Mar 8, 2022 ↗View →
CMMB
CHEMOMAB THERAPEUTICS LTD.
PURCHASEGRANT
Stock grant
6,820——6,820Mar 7, 2022Mar 9, 2022 ↗View →
CMMB
CHEMOMAB THERAPEUTICS LTD.
PURCHASEGRANT
Stock grant
11,884——11,884Apr 19, 2021Mar 9, 2022 ↗View →
CMMB
CHEMOMAB THERAPEUTICS LTD.
PURCHASEGRANT
Stock grant
11,884——11,884Apr 19, 2021Apr 21, 2021 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,726——11,852Mar 3, 2021Mar 5, 2021 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,518——5,518Mar 3, 2021Mar 5, 2021 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
3,685——3,685Feb 28, 2020Feb 28, 2020 ↗View →
SRPT
SAREPTA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,075——9,126Feb 28, 2020Feb 28, 2020 ↗View →
Other insiders · GANX
Loading peer insiders…
About this filer
CIK 0001644162
ROLE
Director
PRIMARY
GANX
COMPANIES
4
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001644162DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback